mRNA Vaccine Market to be dominated by 8.34% CAGR through 2030F

Rising incidence of chronic and infectious diseases is expected to drive the growth of Global mRNA Vaccine Market in the forecast period.

According to TechSci Research report, “mRNA Vaccines Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F”, Global mRNA Vaccine Market was valued at USD 11.45 billion in 2024 and is expected to reach USD 18.37 Billion by 2030 with a CAGR of 8.34%. The market is expected to witness significant growth in the forecasted years also due to the growing research activities on the development of mRNA Vaccines for various communicable and non-communicable diseases such as cancer, HIV, influenza, kidney problems, among others. Globally, around 38.4 million people were living with HIV in 2021. 54% of all people living with HIV were women and girls. Around 1.5 million people became newly infected with HIV in 2021. About 650,000 people died from AIDS-related illnesses in 2021.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global mRNA Vaccines Market"

Global mRNA Vaccines Market can be segmented by mRNA type, by application, and by region.

Based on application, COVID-19 mRNA vaccines represent the fastest-growing segment in the global mRNA vaccine market, having transformed the landscape of vaccine development and delivery since 2020. Spearheaded by Pfizer-BioNTech and Moderna, these vaccines were the first mRNA-based products to receive emergency use authorization and full regulatory approval worldwide. Their rapid deployment led to billions of doses administered globally, solidifying both public trust and commercial confidence in mRNA technology. The pandemic catalyzed record-breaking investments, rapid manufacturing scale-ups, and global infrastructure tailored specifically for mRNA platforms—accelerating growth at an unprecedented pace. As a result, COVID-19 vaccines became not just the first successful application of mRNA, but also the most commercially impactful, outpacing other vaccine candidates in development. While non-COVID-19 mRNA vaccines targeting influenza, Zika, and cytomegalovirus are progressing through clinical trials and early commercialization, they have yet to match the scale, speed, or market penetration of their COVID-19 counterparts. Similarly, mRNA-based therapeutics for cancer, rare diseases, and autoimmune conditions—grouped under the "Others" category—show great potential but remain largely in early-stage research.

Based on region, the Asia-Pacific region is the fastest-growing market for mRNA vaccines due to rising investments in biotechnology, increasing government support for local vaccine manufacturing, and growing demand for advanced healthcare solutions. Countries like China, India, Japan, and South Korea are expanding their R\&D infrastructure and forming strategic partnerships with global pharmaceutical firms. The region’s large population, improving healthcare access, and focus on pandemic preparedness are accelerating mRNA vaccine adoption. Initiatives to build decentralized manufacturing hubs and regulatory reforms are further driving clinical trials and commercialization. This momentum positions Asia-Pacific as a key growth engine for the global mRNA vaccine market.

Major companies operating in Global mRNA Vaccines Market are:

·         Arcturus Therapeutics Holdings Inc.

·         BioNTech SE

·         CureVac N.V.

·         Daiichi Sankyo Company Limited.

·         Ethris GmbH

·         GlaxoSmithKline plc

·         Gennova Biopharmaceuticals Ltd

·         Moderna, Inc.

·         Pantherna Therapeutics GmbH

·         Providence Therapeutics

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“mRNA Vaccine market will witness robust growth during the forecast period owing to the advancement of mRNA technologies to produce mRNA vaccines to prevent infectious or chronic diseases. The prevalence of chronic disease will also boost the growth of market. mRNA vaccines are the rapidly producing vaccine comparative to other vaccines produced from biological means. The increasing research & development in the domain of vaccine production through mRNA all over the world will also affect the market growth, positively”, said Mr. Karan Chechi, Research Director of TechSci Research, a research based global management consulting firm.

“mRNA Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA), By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others), Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global mRNA Vaccines Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global mRNA Vaccines Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com